Back
New Oriental Education & Technology Group 10K Form
Buy
65
EDU
New Oriental Education & Technology Group
Last Price:
79.59
Seasonality Move:
12.4%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive EDU News And Ratings
See the #1 stock for the next 7 days that we like better than EDU
EDU Financial Statistics
Sales & Book Value
| Annual Sales: | $4.31B |
|---|---|
| Cash Flow: | $376.84M |
| Price / Cash Flow: | 11.99 |
| Annual Sales: | $22.92 |
| Price / Book: | 3.49 |
Profitability
| EPS (TTM): | 1.90000 |
|---|---|
| Net Income (TTM): | $309.59M |
| Gross Margin: | $2.26B |
| Return on Equity: | 7.71% |
| Return on Assets: | 4.43% |
New Oriental Education & Technology Group Earnings Forecast
Key New Oriental Education & Technology Group Financial Ratios
- The Gross Profit Margin over the past 22 years for EDU is 52.45%.
- The Selling, General & Administrative Expenses for EDU have been equal to 44.33% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 0.10% of Operating Income.
- The Net Earning history of EDU is 7.18% of Total Revenues.
- Per Share Earnings over the last 22 years have been positive in 16 years.
New Oriental Education & Technology Group Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Diversified Consumer Services |
| Sector: | Consumer Discretionary |
| Current Symbol: | EDU |
| CUSIP: | 647581 |
| Website: | neworiental.org |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 1.8 |
| Quick Ratio: | 1.66 |
Price-to-Earnings
| Trailing P/E Ratio: | 44.78 |
|---|---|
| Forward P/E Ratio: | 17.62 |
EDU Technical Analysis vs Fundamental Analysis
Buy
65
New Oriental Education & Technology Group (EDU)
is a Buy
Is New Oriental Education & Technology Group a Buy or a Sell?
-
New Oriental Education & Technology Group stock is rated a Buy
The current New Oriental Education & Technology Group [EDU] share price is $80.60. The Score for EDU is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.